Studies suggested that activated EGFR may be a promising predictor of primary sorafenib resistance in HCC cells, and overexpression of EGFR or its ligands may result in continuous activation of EGFR downstream pathways and subsequent resistance to sorafenib (65). Here, EGFR is linked to hepatocellular carcinoma.